In this Q&A, David Butler, chief technology officer at Hongene Biotech answers three key questions to provide more detail about the partnership.
Hongene Biotech
Redefining gene editing development and manufacturing
In this Q&A, David Butler, Chief Technology Officer at Hongene Biotech answers three key questions to provide more detail about the partnership.
Published:
|
3 min read
Last updated:
Sign up to our newsletter
The week's biggest stories from this industry, direct to your inbox.